Tinzaparin

Generic Name: Tinzaparin

Brand Names: Innohep

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9041-08-1

Unique Ingredient Identifier: 7UQ7X4Y489

Background: Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III...

Indication: Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing c...

Associated Conditions: Clotting, Deep Vein Thrombosis, Pulmonary embolism, Deep vein thrombosis, Venous Thromboembolism

Associated Therapies: -

Clinical Trials

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

Phase 4

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: tinzaparin
Drug: acenocoumarol

First Posted Date: 2008-06-03

Last Posted Date: 2008-06-03

Lead Sponsor: Hospital Universitari de Bellvitge

Target Recruit Count: 241

Registration Number: NCT00689520

Locations: 🇪🇸
Vascular surgery service. Hospital Creu Roja de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Department of Vascular Surgery. Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients

Not Applicable

Completed

Conditions: Primary Brain Tumor

Interventions: Drug: Innohep

First Posted Date: 2008-03-06

Last Posted Date: 2013-01-07

Lead Sponsor: Duke University

Target Recruit Count: 40

Registration Number: NCT00629447

Locations: 🇺🇸
Duke University Health Systems, Durham, North Carolina, United States

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 1

Conditions: Kidney Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2013-11-06

Lead Sponsor: University of Vermont

Target Recruit Count: 35

Registration Number: NCT00293501

Locations: 🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States

The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section

Phase 2

Completed

Conditions: Deep Vein Thrombosis

First Posted Date: 2005-09-23

Last Posted Date: 2018-02-07

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 30

Registration Number: NCT00225108

Locations: 🇨🇦
Ottawa Hospital, Ottawa, Ontario, Canada

Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin

Phase 4

Completed

Conditions: Thrombosis
Thromboembolism
Venous Thrombosis

First Posted Date: 2005-09-20

Last Posted Date: 2007-02-09

Lead Sponsor: University of Calgary

Target Recruit Count: 400

Registration Number: NCT00203658

Locations: 🇨🇦
Thrombosis Research Unit, University of Calgary, Calgary, Alberta, Canada

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

Phase 4

Completed

Conditions: Thrombosis
Thromboembolism
Venous Thrombosis

First Posted Date: 2005-09-20

Last Posted Date: 2007-02-09

Lead Sponsor: University of Calgary

Target Recruit Count: 910

Registration Number: NCT00203580

Locations: 🇨🇦
Thrombosis Research Unit, University of Calgary, Calgary, Alberta, Canada

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Not Applicable

Terminated

Conditions: Venous Thrombosis
Pulmonary Embolism

Interventions: Drug: Tinzaparin

First Posted Date: 2005-09-16

Last Posted Date: 2016-04-19

Lead Sponsor: St. Joseph's Healthcare Hamilton

Target Recruit Count: 148

Registration Number: NCT00186745

Locations: 🇨🇦
St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Not Applicable

Terminated

Conditions: Peritoneal Dialysis
Nutrition
Inflammation

First Posted Date: 2005-08-26

Last Posted Date: 2015-05-21

Lead Sponsor: Ribe County Hospital

Target Recruit Count: 36

Registration Number: NCT00135863

Locations: 🇩🇰
Ribe County Hospital, Esbjerg, Ribe, Denmark

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Aspirin
Drug: tinzaparin sodium
Drug: eptifibatide

First Posted Date: 2003-05-26

Last Posted Date: 2013-02-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 18

Registration Number: NCT00061373

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Suburban Hospital, Bethesda, Maryland, United States
🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy